Table 1.
Baseline characteristics of the study cohort
| Characteristic | Value (n=55) |
|---|---|
| Men (%) | 45 |
| Age | |
| Mean±SD (yr) | 59±15 |
| Age distribution (%) | |
| 18–49 | 33 |
| 50–69 | 40 |
| 70–79 | 22 |
| 80–90 | 5 |
| Hemodialysis (%) | 51 |
| Dialysis sessions per week (n) | 3 |
| Duration of dialysis session (h) | 5.1±0.7 |
| Single pool Kt/V | 1.73±0.38 |
| Interdialytic weight gain (kg) | 1.7 (1.5–2.3) |
| Interdialytic weight gain relative to estimated dry weight (%) | 2.3±1 |
| Peritoneal dialysis (%) | 49 |
| Volume of peritoneal dialysis solution exchanged per 24 h (L) | 8 (8–10) |
| 4-h D/P creatinine | 0.72±0.52 |
| Weekly Kt/V | 2.21 (1.95–2.49) |
| Time on dialysis (mo) | 35 (16–58) |
| Body mass index (kg/m2) | 30.2 (28.5–34.6) |
| Systolic BP (mmHg) | 130±15 |
| Diastolic BP (mmHg) | 74±12 |
| Diabetes mellitus (%) | 40 |
| Current or former smoker (%) | 51 |
| Ischemic heart disease (%) | 22 |
| Peripheral vascular disease and/or cerebrovascular disease (%) | 9 |
| Hydration status | |
| Ratio of extracellular to total body water | 0.48±0.04 |
| Overhydration volume relative to extracellular volume (%) | 3±9 |
| Normohydrated (%) | 69 |
| Moderately overhydrated (%) | 21 |
| Severely overhydrated (%) | 10 |
| Left ventricular structure and function | |
| Left ventricular hypertrophy (%) | |
| Nil | 56 |
| Mild | 33 |
| Moderate | 11 |
| Ejection fraction (%) | 60±7 |
| Left ventricular systolic dysfunction (%) | 9 |
| Diastolic dysfunction (%) | |
| Nil | 13 |
| Mild | 24 |
| Moderate | 45 |
| Severe | 18 |
| Antihypertensive agents | |
| Median number of antihypertensive agents | 1 (1–2) |
| Proportion taking β-blockers (%) | 42 |
| Proportion taking ACEIs or ARBs (%) | 38 |
| C-reactive protein (mg/L) | 5.0 (2.1–12) |
| NT-proBNP (pg/ml) | |
| Median (interquartile range) | 1698 (718–3742) |
| Distribution (%) | |
| <300 | 7 |
| 300–899 | 20 |
| 900–4999 | 51 |
| 5000–19,999 | 11 |
| ≥20,000 | 11 |
D/P creatinine, ratio of creatinine concentration in dialysate to plasma; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin type 1 receptor blocker; NT-proBNP, N-terminal pro–B-type natriuretic peptide.